Infinity Licenses PI3K Program From Intellikine in $489M Deal

Infinity Pharmaceuticals Inc. signed a $488.5 million global licensing deal for Intellikine Inc.'s preclinical phosphoinositide-3 kinase (PI3K) delta and gamma inhibitors, including lead compound INK1197, an oral small molecule slated to begin clinical trials for inflammatory diseases in 2011. (BioWorld Today)